Alanyl Glutamine

Alanyl Glutamine

SCHEMBL31353025

C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)O.N[C@@H](CCC(=O)O)C(=O)O

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOD1 Q9Y239 3/20 0.61
ALOX15 P16050 1/20 0.54
BLM P54132 1/20 0.54
PMP22 Q01453 1/20 0.54
KMT2A Q03164 1/20 0.54
GRM8 O00222 1/20 0.51
GRM6 O15303 1/20 0.51
GRIN2D O15399 1/20 0.51
GRIN3B O60391 1/20 0.51
GSR P00390 1/20 0.51
CYP1A2 P05177 1/20 0.51
GRIK1 P39086 1/20 0.51
GRM5 P41594 1/20 0.51
GRIA1 P42261 1/20 0.51
GRIA2 P42262 1/20 0.51
GRIA3 P42263 1/20 0.51
SLC1A3 P43003 1/20 0.51
SLC1A2 P43004 1/20 0.51
SLC1A1 P43005 1/20 0.51
GRIA4 P48058 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alanyl Glutamine SCHEMBL1692194 0.96 NOD1 (0.65) NOD1ALOX15BLMPMP22KMT2A
Alanyl Glutamine SCHEMBL6516788 0.96 NOD1 (0.65) NOD1ALOX15BLMPMP22KMT2A
Alanyl Glutamine SCHEMBL1692197 0.96 NOD1 (0.65) NOD1ALOX15BLMPMP22KMT2A
SCHEMBL31627965 0.91 NOD1 (0.53) NOD1KMT2AFOLH1NAALAD2RIMKLA
SCHEMBL29772065 0.91 NOD1 (0.53) NOD1KMT2AFOLH1NAALAD2RIMKLA
SCHEMBL30193304 0.91 NOD1 (0.53) NOD1KMT2AFOLH1NAALAD2RIMKLA
Alanyl Glutamine SCHEMBL4274839 0.89 NOD1 (0.59) NOD1ALOX15BLMPMP22KMT2A
Alanyl Glutamine SCHEMBL8427100 0.89 NOD1 (0.59) NOD1ALOX15BLMPMP22KMT2A
Alanyl Glutamine SCHEMBL31140886 0.89 NOD1 (0.59) NOD1ALOX15BLMPMP22KMT2A
Alanyl Glutamine SCHEMBL133886 0.89 NOD1 (0.59) NOD1ALOX15BLMPMP22KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085288-A1 METHOD OF DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO HEMATOPOIETIC PRECURSOR AND STEM CELLS SCHERER TECHNOLOGIES LLC R P (US) 2026-03-26 US disclosed
CN-120153063-A Method for differentiating pluripotent stem cells into hematopoietic precursor cells and stem cells R.P.谢勒技术有限责任公司 2025-06-13 CN disclosed
CN-120040593-A Anti-HER 2 binding molecules 瑟缇斯治疗私人有限公司 2025-05-27 CN disclosed
CN-113993902-B Anti-HER 2 binding molecules 瑟缇斯治疗私人有限公司 2025-03-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085288-A1 METHOD OF DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO HEMATOPOIETIC PRECURSOR AND STEM CELLS BMP4, WNT3A, KIT NOD1 1547/4885ALOX15 4376/4885BLM 3198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.